• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Details emerge in federal case against Stryker Biotech

Details emerge in federal case against Stryker Biotech

October 29, 2009 By MassDevice staff

A federal indictment brought by a Boston grand jury against Stryker Biotech sheds light on the charges against the company and the four managers charged with a two-year campaign to promote the off-label combination of two bone growth products and lying to the FDA.

The Hopkinton, Mass.-based firm and its former president, Mark Philip, along with sales managers David Ard, Jeff Whitaker and William Heppner, were indicted by a grand jury on charges of wire fraud and conspiracy. Stryker and Philip were also charged with making false statements to the FDA.

Heppner was the company’s national sales director; Ard and Whitaker were regional managers for the western and central territories, respectively.

The indictment alleges that the defendants were part of a scheme to promote the combined use of a pair of separate bone-healing products, each granted a narrow, provisional “humanitarian device exemption” by the FDA.

Combining the treatments and devices — the OP-1 Implant, OP-1 Putty and the bone void filler Calstrux — caused adverse effects in patients ranging from minor irritations to infections requiring follow-up surgeries.

The indictment also charges that Stryker and Philip lied to the FDA about the number of patients treated each year with OP-1 Putty.

Here’s a timeline of the alleged misdeeds, according to a copy of the indictment obtained by MassDevice:

Early 2005:

  • Stryker launches Calstrux after winning 510(k) approval from the FDA for its use as a bone void filler — and not for use in combination with the OP-1 products. Nevertheless, Stryker allegedly presents Calstrux to its sales force as a “carrier” or “extender” for those products. Philip notes that Calstrux should “accelerate” OP-1 sales
  • Philip, Heppner, Ard and Whitaker allegedly promoted “recipes” for combining the products to surgeons. The mixing instructions varied, with some recommending surgeons form “cigars,” some advising “Tootsie rolls,” “bricks” or “Vienna sausages.” The alleged recipes also vary according to the type and amount of liquid (blood or saline solution) and how much Calstrux to use. As one sales rep allegedly wrote to senior Stryker managers, “Like any product if we have 30+ people doing something different with regards to mixing, dosing, etc. we are going to see different results.”

Mid-2005:

  • Stryker Biotech allegedly begins receiving reports of adverse events from the combination of the OP-1 products and Calstrux, including inflammation, drainage and impaired wound healing. Some patients required additional surgeries, which revealed that the mixture migrated from site of the procedure.
  • In some of those cases, surgeons allegedly observed that the mixture resembled “oatmeal,” “grits” or “white sesame seeds.” In some cases, the mixture allegedly stimulated the growth of bone spurs where it migrated; some of those cases required surgical removal of the spurs.

Early 2006

  • The company allegedly commissions a report from a surgeon analyzing the results of the combination. His report allegedly reveals an adverse event rate higher than with standard treatments for long-bone fractures.
  • Later in 2006, the surgeon allegedly tells Stryker that the mixture is not effective.
  • Stryker allegedly touts Calstrux as the “perfect carrier for OP-1” in a January sales meeting — despite the adverse event reports and the surgeon’s recommendation.
  • In mid-February, a senior Stryker Biotech manager, not named in the indictment, allegedly sends a memo to colleagues including Philip detailing concerns about the adverse event reports, that “a variety of different ‘recipes’ are used” to mix the products and that Calstrux was being improperly promoted as the “preferred carrier” for OP-1.
  • The manager allegedly recommends that Stryker stop “recommending, suggesting and preparing for use [of] Calstrux and OP-1 Implant as noted above” and that the company issue a “dear doctor” letter advising surgeons of the adverse events.

  • Heppner, Whitaker and other sales managers argue against the “dear doctor” letter, saying it would harm OP-1 sales, anger the surgeons who were duped into using the mixture because “many surgeons are just handed the product prior to implantation and think it’s all OP-1,” and cause the independent review boards charged with making sure treatments are safe for patients to rescind their approvals of the OP-1 product.
  • In March, a Stryker Biotech VP allegedly told the sales force in a training session, including Heppner, Ard and Whitaker, that promoting the combination of the products could expose the company and its employees to criminal prosecution. The VP allegedly warned that such promotion could lead to a product recall, the FDA shutting down the company, criminal misbranding prosecution and “enormous criminal fines and civil penalties.”
  • Also in early March, Philip allegedly nixes the “dear doctor” letter.

2006- 2008

  • The four defendants allegedly continue to promote the combination of OP-1 and Calstrux until roughly February 2008.

In a prepared statement, Stryker said it is “disappointed” about the indictment and “still hopes to be able to reach a fair and just resolution of this matter.”

“Conviction of these charges could result in significant monetary fines and Stryker Biotech’s exclusion from participating in federal and state health care programs, which could have a material affect on Stryker Biotech’s business,” according to the statement. “As a matter of company policy Stryker will not have any further comment on these allegations.”

Filed Under: Business/Financial News, Orthopedics

In case you missed it

  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy